Acceleron Pharma Inc., of Cambridge, Mass., named Niels Borgstein vice president of medical research.

Adlyfe Inc., of Rockville, Md., appointed Roxanne Duan vice president of research.

Alexza Pharmaceuticals Inc., of Palo Alto, Calif., named Robert Fishman vice president of medical affairs.

Amgen Inc., of Thousand Oaks, Calif., appointed Vance Coffman to its board.

Amira Pharmaceuticals Inc., of San Diego, named Hari Kumar chief business officer.

AM-Pharma BV, of Bunnik, the Netherlands, appointed Erik van den Berg chief business officer.

Anacor Pharmaceuticals Inc., of Palo Alto, Calif., appointed Paul Cleveland to its board.

Nitec Pharma AG, of Reinach, Switzerland, appointed Anders Harfstrand CEO and Andrea Buscaglia chief financial officer.

Nventa Biopharmaceuticals Corp., of San Diego, named David Duncan vice president of finance.

Pharmacopeia, of Princeton, N.J., appointed Eric Liebler executive vice present of corporate development and S. David Kimball senior vice president of chemistry and preclinical chemical development.

Prolog Ventures, of St. Louis, added Dan Broderick as partner.

Redpoint Bio Corp., of Ewing, N.J., appointed Allen Bloom, Irwin Scher and Richard Shanley to its board.

Resolvyx Pharmaceuticals Inc., of Bedford, Mass., appointed James Nichols executive vice president of corporate development.

Rheosciences A/S, of Copenhagen, Denmark, appointed Swami Subramaniam director of business development.

Quark Pharmaceuticals Inc., of Fremont, Calif., named J. Joseph Marr chief medical officer.

Venrock, of Menlo Park, Calif., named Steve Goldby as partner and Ken Song as vice president.

XenoPort Inc., of Santa Clara, Calif., appointed Catherine Friedman to its board.